We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Citigroup Announces Restructuring of Sales and Trading Unit
Read MoreHide Full Article
Citigroup (C - Free Report) is set to merge two key divisions in its sales and trading unit — foreign-exchange and rates businesses. This move will mark the first major overhaul after Paco Ybarra took position as head of institutional-clients group in April 2019.
The restructuring is expected to support the bottom line as the two divisions complement each other by sharing technology and corporate-sales teams and having overlapping products. Co-heads of the markets division, Carey Lathrop and Andy Morton said, "We believe this more streamlined operating model will drive better client service, risk management and profitability."
Notably, the G10 Rates Finance unit will not be merged into the new combined rates and currencies business.
Also, there has been some management shakeup under which, Nadir Mahmud, who previously looked after foreign exchange and local markets division, will work with Leo Arduini on Europe, the Middle East and Africa strategy. Arduini manages the sales and trading business in the region.
Deidre Dunn, who led Citi’s trading business in North America, will co-head rates trading with Pedro Goldbaum.
Other Wall Street Restructurings
So far in June 2019, several restructurings have been announced by Wall Street firms. Some aim at achieving cost cuts while others target to streamline and simplify their operation to focus more on core businesses.
Let’s have a look at some restructurings announced recently;
Goldman Sachs (GS - Free Report) is integrating four separate private-investment groups into a single unit that would comprise arms investing in private companies, real estate and other hard-to-access deals with total assets worth $140 billion. The move is aimed to make Goldman’s alternative division more appealing to investors and help boost stock price.
Also, Wells Fargo (WFC - Free Report) announced major overhaul of its Commercial Banking unit by combining Business Banking, Government & Institutional Banking and Middle Market Banking businesses. It expects to further improve customer experience through this move.
The new structure will be headed by Kyle Hranicky, who has been serving Wells Fargo for the past 25 years. It will have more than 6,000 team members across 24 divisions and 80 markets nationwide, and cater to all the financial needs of customers.
Our Viewpoint
Restructuring of businesses is always good news as it reflects management’s focus on improving the company’s performance.
Citigroup continues to execute growth strategies, such as making entry into the booming digital consumer payments industry and expanding global market presence, thereby aiming to diversify revenue sources.
Over the past six months, the stock has gained 26% compared with 12.7% growth recorded by the industry.
Another top-ranked stock in the same space is M&T Bank Corporation (MTB - Free Report) . It has witnessed slight upward estimate revisions for current-year earnings over the past 60 days. Over the past six months, the company’s share price has been up 16.5%. It currently carries a Zacks Rank of 2.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
Image: Bigstock
Citigroup Announces Restructuring of Sales and Trading Unit
Citigroup (C - Free Report) is set to merge two key divisions in its sales and trading unit — foreign-exchange and rates businesses. This move will mark the first major overhaul after Paco Ybarra took position as head of institutional-clients group in April 2019.
The restructuring is expected to support the bottom line as the two divisions complement each other by sharing technology and corporate-sales teams and having overlapping products. Co-heads of the markets division, Carey Lathrop and Andy Morton said, "We believe this more streamlined operating model will drive better client service, risk management and profitability."
Notably, the G10 Rates Finance unit will not be merged into the new combined rates and currencies business.
Also, there has been some management shakeup under which, Nadir Mahmud, who previously looked after foreign exchange and local markets division, will work with Leo Arduini on Europe, the Middle East and Africa strategy. Arduini manages the sales and trading business in the region.
Deidre Dunn, who led Citi’s trading business in North America, will co-head rates trading with Pedro Goldbaum.
Other Wall Street Restructurings
So far in June 2019, several restructurings have been announced by Wall Street firms. Some aim at achieving cost cuts while others target to streamline and simplify their operation to focus more on core businesses.
Let’s have a look at some restructurings announced recently;
Goldman Sachs (GS - Free Report) is integrating four separate private-investment groups into a single unit that would comprise arms investing in private companies, real estate and other hard-to-access deals with total assets worth $140 billion. The move is aimed to make Goldman’s alternative division more appealing to investors and help boost stock price.
Also, Wells Fargo (WFC - Free Report) announced major overhaul of its Commercial Banking unit by combining Business Banking, Government & Institutional Banking and Middle Market Banking businesses. It expects to further improve customer experience through this move.
The new structure will be headed by Kyle Hranicky, who has been serving Wells Fargo for the past 25 years. It will have more than 6,000 team members across 24 divisions and 80 markets nationwide, and cater to all the financial needs of customers.
Our Viewpoint
Restructuring of businesses is always good news as it reflects management’s focus on improving the company’s performance.
Citigroup continues to execute growth strategies, such as making entry into the booming digital consumer payments industry and expanding global market presence, thereby aiming to diversify revenue sources.
Over the past six months, the stock has gained 26% compared with 12.7% growth recorded by the industry.
Currently, Citi carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Another top-ranked stock in the same space is M&T Bank Corporation (MTB - Free Report) . It has witnessed slight upward estimate revisions for current-year earnings over the past 60 days. Over the past six months, the company’s share price has been up 16.5%. It currently carries a Zacks Rank of 2.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>